Grant: Undergraduate Student Research Awards (USRA)
McGill University
$6,000.00
Characterization of hERG mutant cardiomyocytes derived from human pluripotent stem cells
EF 2025-26
Résumé
Long QT syndrome Type 2 (LQTS2) is due to mutations in the human ether-a-go-go related gene (hERG) causing prolongation of the ventricular action potential duration that leads to potentially lethal cardiac arrhythmias. Using non-cardiac hERG expressing cell lines we reported that hERG mutants have reduced cell surface hERG channel expression and recently identified FDA approved drugs that partially correct surface expression, which must be validated in human cardiac cells. Towards this end we have recently generated human induced pluripotent stem cells (hi-PSCs) engineered with CRISPR/CAS9 to express extracellular HA-tagged WT and PAS domain mutant (T65P) hERG channels. The goal of this summer research project is for Fedgi to differentiate the engineered hi-PSCS to generate cardiomyocytes (CMs) that he will characterize with regards to their function and hERG channel localization. This involves three aims: 1) To characterize WT and mutant CM monolayer cultures using dye-free imaging of contraction transients to assess spontaneous beat rate, conduction velocity, and contraction/relaxation interval (CRI), as an index of the action potential duration; 2) To use genetically modified HEK cells, expressing light-sensitive optogenetically activated channelrhodopsin-2 (CHR2), that couple to and can optically pace the CMs to assess the CRI in paced monolayer cultures; 3) To characterize the cellular localization of the HA-tagged hERG channels in WT and T65P CMs using anti-HA antibody to label extracellular cell surface HA-hERG in fixed monolayers and then HA-hERG intracellular distribution after cell permeabilization with saponin. This project will set the groundwork for further electrophysiological and biochemical studies of mutant hERG channel drug rescue.
Programme
Undergraduate Student Research Awards (USRA)
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
531018
Name
Gaspard Fedgi Dony
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterization of hERG mutant cardiomyocytes derived from human pluripotent stem cells
Programtype2
Miscellaneous Programs
Orgnameinp2
McGill University
Cihramount2
$6,000
Cihrequipment2
$0
Programname2
Undergraduate Student Research Awards (USRA)
Keyworddelim
Arrhythmias; Cell Lines; Gene; Genetically Modified; Human Cardiac Cells; Mutants; Mutations; Qt Syndrome
Abstract
Long QT syndrome Type 2 (LQTS2) is due to mutations in the human ether-a-go-go related gene (hERG) causing prolongation of the ventricular action potential duration that leads to potentially lethal cardiac arrhythmias. Using non-cardiac hERG expressing cell lines we reported that hERG mutants have reduced cell surface hERG channel expression and recently identified FDA approved drugs that partially correct surface expression, which must be validated in human cardiac cells. Towards this end we have recently generated human induced pluripotent stem cells (hi-PSCs) engineered with CRISPR/CAS9 to express extracellular HA-tagged WT and PAS domain mutant (T65P) hERG channels. The goal of this summer research project is for Fedgi to differentiate the engineered hi-PSCS to generate cardiomyocytes (CMs) that he will characterize with regards to their function and hERG channel localization. This involves three aims: 1) To characterize WT and mutant CM monolayer cultures using dye-free imaging of contraction transients to assess spontaneous beat rate, conduction velocity, and contraction/relaxation interval (CRI), as an index of the action potential duration; 2) To use genetically modified HEK cells, expressing light-sensitive optogenetically activated channelrhodopsin-2 (CHR2), that couple to and can optically pace the CMs to assess the CRI in paced monolayer cultures; 3) To characterize the cellular localization of the HA-tagged hERG channels in WT and T65P CMs using anti-HA antibody to label extracellular cell surface HA-hERG in fixed monolayers and then HA-hERG intracellular distribution after cell permeabilization with saponin. This project will set the groundwork for further electrophysiological and biochemical studies of mutant hERG channel drug rescue.
Competitiondate
202505
Approvedterm2
0 yr 4 mths
Pinamesdelim
Gaspard, Fedgi Dony
Approvedterm
0 an 4 mois
Cihrcontribution2
~ $6,000~ $0~